Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...

Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.

Start 7-day free trial → Log in

Enozertinib · ORIC-114

Small molecule · Inhibitor of EGFR and HER2 (ERBB2) · developed by ORIC Pharmaceuticals

Phase 1/2 Most advanced trial

ORIC Developer

1 Registered trials

What is Enozertinib?

Enozertinib is an orally bioavailable, CNS-penetrating covalent inhibitor of mutant EGFR and HER2, particularly exon 20 insertion mutations. It irreversibly binds to and inhibits EGFR/HER2-mediated signaling, inducing cell death in overexpressing tumor cells and potentially targeting CNS primary tumors and metastases.

Summary written with AI from the sources listed at the end of this page.

At a glance

Also known as: ORIC-114
Drug type: Small molecule
Targets: EGFR, HER2 (ERBB2)
Mechanism: Inhibitor of EGFR and HER2 (ERBB2)
Pathways: EGFR/HER2-mediated signaling
Therapy area: Oncology
Developer: ORIC Pharmaceuticals (ORIC)
FDA status: Investigational, not approved in the US. Most advanced trial: Phase 1/2
UNII: DU24UP8R94

🧪 Clinical trials

Trial	Phase	Condition	Status	Sponsor
NCT05315700	Phase 1/2	Solid Tumors	Recruiting	ORIC

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

Solid Tumors

Other drugs acting on EGFR / ERBB2

Neratinib FDA approved Osimertinib FDA approved Trastuzumab Deruxtecan FDA approved Trastuzumab Emtansine FDA approved Zanidatamab FDA approved Actinium Ac 225 FPI-2068 Phase 1 ADCT-502 Phase 1 ALX2004 Phase 1 BH-30643 Phase 1/2 CGT4255 Phase 1 CUDC-101 Phase 1 EGFR-TKI inhibitor based on investigator's choice Phase 3

More from ORIC Pharmaceuticals

ORIC-101 Phase 1 ORIC-533 Phase 1 Rinzimetostat Phase 3

Sources

NCI Thesaurus

Updated Oct 3, 2026. Something wrong or missing? Report it on the ORIC page.

Follow ORIC, the company behind Enozertinib

See ORIC's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.

ORIC catalysts and pipeline →

Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z